Characteristics of Hospitalized Patients With Community-acquired Pneumonia

Community-acquired Pneumonia Clinical Trial

Official title:

A Retrospective Study on Disease Characteristics of Hospitalized Patients With Community-acquired Pneumonia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06065618
• Other study ID #: YXLL-KY-2022(080)
• Status: Recruiting
• Start date: September 22, 2023
• Est. completion date: September 22, 2024

Study information

• Verified date: October 2023
• Source: Qianfoshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

At present, the epidemiological characteristics and the distribution of pathogens of community-acquired pneumonia in Shandong Province are not clear. In order to understand the characteristics of community-acquired pneumonia, the distribution of pathogens and the risk factors of complications in Shandong Province, it is necessary to carry out investigation and study, which will provide the basis and support for the future prospective cohort study of pulmonary infection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: September 22, 2024
• Est. primary completion date: September 22, 2024
• Gender: All
• Age group: 14 Years and older

Eligibility

Inclusion Criteria:

• Age > 14 years.

• In the community.

• Chest X-ray showed patchy, patchy infiltrative shadows or interstitial changes with or without pleural effusion (in or out of hospital) .

• Pneumonia-related clinical manifestations: 1) recent cough, expectoration or respiratory disease symptoms aggravated, and the emergence of purulent sputum, with or without chest pain. 2) fever: armpit temperature =37.3? or hypothermia: armpit temperature <36?. 3) signs of pulmonary consolidation and/or Wet Rales. 4) white blood cell > 10 × 10^9/L or < 4 × 10^9/L with or without left shift of nucleus. Comply with 1,2,3 above plus any one of 4 above.

Exclusion Criteria:

• The patients were initially diagnosed with pulmonary neoplasms, tuberculosis, non-infectious interstitial disease, pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophil granulocyte infiltration and pulmonary vasculitis.

• Human Immunodeficiency Virus.

• The patient was readmitted within 72 hours of discharge and was classified as a single hospitalization.

Related Conditions & MeSH terms

• Community-acquired Pneumonia
• Pneumonia

Intervention

Other:
• Without intervention
Without intervention

Locations

Country	Name	City	State
China	Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qianfoshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The prevalence of CAP	The prevalence of CAP	Up to 12 months
Secondary	Severity Assessment: Curb-65	Curb-65 is mainly used to evaluate the severity of pneumonia. The clinical indexes of curb-65 include: 1. Disturbance of consciousness, 2. Blood urea nitrogen > 7 mmol/L, 3. Respiratory frequency =30 times/min, 3. The severity of pneumonia 4. Systolic blood pressure < 90 mmhg or diastolic blood pressure =60 mmhg. 5. Age =65 years. If curb-65 score is 0-1, it is recommended that the patient be treated outside the hospital. Curb-65 has a score of 2 and is recommended for short-term hospitalization. If curb-65 score =3 indicates severe pneumonia, hospitalization or ICU treatment is recommended. With the increase of curb-65 score, the mortality of the patients will increase accordingly.	Up to 12 months
Secondary	Sputum culture	According to the need for aerobic bacteria culture, anaerobic bacteria culture, Mycobacterium tuberculosis culture, or fungal culture, for the etiological diagnosis of respiratory infection.	Up to 12 months